keyword
MENU ▼
Read by QxMD icon Read
search

cilostazol

keyword
https://www.readbyqxmd.com/read/28324691/comparison-of-three-different-types-of-cilostazol-loaded-solid-dispersion-physicochemical-characterization-and-pharmacokinetics-in-rats
#1
Omer Mustapha, Kyung Soo Kim, Shumaila Shafique, Dong Shik Kim, Sung Giu Jin, Youn Gee Seo, Yu Seok Youn, Kyung Taek Oh, Chul Soon Yong, Jong Oh Kim, Han-Gon Choi
The aim of this research was to compare three different types of cilostazol-loaded solid dispersion system including solvent-evaporated, solvent-wetted and surface-attached solid dispersion. The effect of polymers and surfactants on the aqueous solubility of cilostazol was investigated, leading to the selection of polyvinylpyrrolidone (PVP) and sodium lauryl sulphate (SLS). Employing a spray-drying technique, numerous surface-attached, solvent-evaporated and solvent-wetted solid dispersions were prepared with various amounts PVP and SLS using water, 90% ethanol and acetone, respectively...
March 9, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/28294544/identification-of-acetylcholinesterase-inhibitors-using-homogenous-cell-based-assays-in-quantitative-high-throughput-screening-platforms
#2
Shuaizhang Li, Ruili Huang, Samuel Solomon, Yitong Liu, Bin Zhao, Michael F Santillo, Menghang Xia
Acetylcholinesterase (AChE) is an enzyme responsible for metabolism of acetylcholine, a neurotransmitter associated with muscle movement, cognition, and other neurobiological processes. Inhibition of AChE activity can serve as a therapeutic mechanism, but also cause adverse health effects and neurotoxicity. In order to efficiently identify AChE inhibitors from large compound libraries, homogenous cell-based assays in high-throughput screening platforms are needed. In this study, a fluorescent method using Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine) and the Ellman absorbance method were both developed in a homogenous format using a human neuroblastoma cell line (SH-SY5Y)...
March 14, 2017: Biotechnology Journal
https://www.readbyqxmd.com/read/28293857/effect-of-cilostazol-in-treating-diabetes-associated-microvascular-complications
#3
REVIEW
Nicole J Asal, Karolina A Wojciak
PURPOSE: Cilostazol (Pletal), a phosphodiesterase-3 inhibitor, was approved in the United States in 1999 to reduce symptoms of intermittent claudication. Cyclic adenosine monophosphate levels increase from inhibition of phosphodiesterase resulting in anti-platelet, anti-inflammatory, and vasodilatory effects. Diabetes mellitus is a chronic disease that causes endothelial and platelet dysfunction leading to both microvascular and macrovascular complications. This mini-review highlights the emerging evidence suggesting benefits of using cilostazol in treating microvascular complications associated with diabetes mellitus...
March 14, 2017: Endocrine
https://www.readbyqxmd.com/read/28290236/efficacy-of-cilostazol-based-dual-antiplatelet-treatment-in-patients-undergoing-carotid-artery-stenting
#4
Ichiro Nakagawa, Hun Soo Park, Takeshi Wada, Shohei Yokoyama, Syuichi Yamada, Yasushi Motoyama, Kimihiko Kichikawa, Hiroyuki Nakase
BACKGROUND: It is essential that patients undergoing carotid artery stenting (CAS) receive optimal antiplatelet inhibition. Although a reduction in platelet reactivity and improved clinical outcomes occur when using adjunctive cilostazol with dual antiplatelet therapy, this can lead to an increased risk of hemorrhagic complications. Therefore, our current study examined patients undergoing CAS and evaluated the impact of cilostazol-based dual antiplatelet treatment on the outcomes. METHODS: Between 2010 and 2015, 137 consecutive patients underwent CAS...
March 14, 2017: Neurological Research
https://www.readbyqxmd.com/read/28255102/randomized-angiographic-and-intravascular-ultrasound-comparison-of-dual-antiplatelet-therapy-vs-triple-antiplatelet-therapy-to-reduce-neointimal-tissue-proliferation-in-diabetic-patients
#5
Maria Fernanda Zuliani Mauro, J Armando Mangione, J Ribamar Costa, Ricardo Costa, Luiz Alberto Piva E Mattos, Rodolfo Staico, Fausto Feres, Dimytri Siqueira, Amanda Sousa, Alexandre Abizaid
BACKGROUND: Previous studies have suggested a benefit of cilostazol in addition to standard dual-antiplatelet therapy (DAPT), reducing in-stent late luminal loss and restenosis after percutaneous coronary intervention (PCI) with bare-metal and drug-eluting stent (DES) implantation. However, there is a paucity of intravascular ultrasound (IVUS) assessment of neointimal tissue hyperplasia (NIH) after triple-antiplatelet therapy (TAPT), especially in diabetic patients treated with DES. METHODS: This prospective, placebo-controlled trial was conducted in diabetic patients randomized (1:1) to receive either standard DAPT (aspirin and clopidogrel) vs TAPT with cilostazol for a minimum of 12 months after PCI with Endeavor zotarolimus-eluting stent (E-ZES)...
March 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/28242396/aggressive-wound-care-by-a-multidisciplinary-team-improves-wound-healing-after-infrainguinal-bypass-in-patients-with-critical-limb-ischemia
#6
Shinsuke Mii, Kiyoshi Tanaka, Ryoichi Kyuragi, Hiroshi Ishimura, Shinsuke Yasukawa, Atsushi Guntani, Eisuke Kawakubo
BACKGROUND: A long period is generally required for ischemic ulcer to heal after revascularization. The strategy of postoperative wound care can affect wound healing. This study was conducted to investigate the degree to which aggressive wound care (AWC) by a team of multidisciplinary specialists actually shortens the time to wound healing and increases the rate of wound healing in limbs undergoing surgical bypass for ischemic tissue loss in a real clinical setting. METHODS: A total of consecutive 126 patients undergoing infrainguinal bypass for tissue loss from April 2011 to March 2015 were reviewed...
February 24, 2017: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/28242395/restenosis-after-coronary-and-peripheral-intervention-efficacy-and-clinical-impact-of-cilostazol
#7
REVIEW
Gianmarco de Donato, Francesco Setacci, Maria Agnese Mele, Giovanni Giannace, Giuseppe Galzerano, Carlo Setacci
Restenosis is one of the main complications in patients undergoing coronary or peripheral revascularization procedures and is the leading cause for their long-term failures. Cilostazol is the only pharmacotherapy that showed an adequate efficacy for preventing restenosis in randomized, controlled studies after coronary or peripheral revascularization procedures. The present review sums up the main clinical evidence supporting the use of cilostazol after revascularization interventions, focusing on all its benefits, warnings and administration schedules...
February 24, 2017: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/28231822/cilostazol-as-an-add-on-therapy-for-patients-with-alzheimer-s-disease-in-taiwan-a-case-control-study
#8
Shu-Yu Tai, Chun-Hung Chen, Chen-Yu Chien, Yuan-Han Yang
BACKGROUND: Combination therapy using acetylcholinesterase inhibitors (AChEIs) and cilostazol is of unknown efficacy for patients with Alzheimer's disease (AD). METHODS: We explored the therapeutic responses by using a case-control study, which was conducted in Taiwan. We enrolled 30 participants with stable AD who were receiving cilostazol (50 mg) twice per day as an add-on therapy combined with AChEIs, and 30 participants as controls who were not receiving cilostazol as an add-on therapy...
February 23, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28219750/release-kinetics-of-highly-porous-floating-tablets-containing-cilostazol
#9
Kyu-Mok Hwang, Cheol-Hee Cho, Nguyen-Thach Tung, Ju-Young Kim, Yun-Seok Rhee, Eun-Seok Park
This study focuses on developing a highly porous floating tablet containing cilostazol. The underlying release mechanism of cilostazol from porous and floating tablets in dissolution media containing surfactants was investigated. The tablets were prepared by compressing granules and excipients with a sublimating agent, followed by sublimation under vacuum. The volatile material for the sublimating agent was chosen based on its flow properties using conventional methods as well as the twisted blade method. Resultant tablets could float immediately and had significantly higher tensile strengths than conventional tablets of similar porosities, holding a promising potential for increasing gastroretentive properties...
February 20, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28208711/antidepressant-effects-of-aripiprazole-augmentation-for-cilostazol-treated-mice-exposed-to-chronic-mild-stress-after-ischemic-stroke
#10
Yu Ri Kim, Ha Neui Kim, Ki Whan Hong, Hwa Kyoung Shin, Byung Tae Choi
The aim of this study was to determine the effects and underlying mechanism of aripiprazole (APZ) augmentation for cilostazol (CLS)-treated post-ischemic stroke mice that were exposed to chronic mild stress (CMS). Compared to treatment with either APZ or CLS alone, the combined treatment resulted in a greater reduction in depressive behaviors, including anhedonia, despair-like behaviors, and memory impairments. This treatment also significantly reduced atrophic changes in the striatum, cortex, and midbrain of CMS-treated ischemic mice, and inhibited neuronal cell apoptosis, particularly in the striatum and the dentate gyrus of the hippocampus...
February 8, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28202868/rt-pa-with-antithrombotic-therapies-in-a-case-with-capsular-warning-syndrome
#11
Yasuhiro Fuseya, Miyuki Kawamura, Eri Matsuda, Kozue Takada, Kiwamu Watanabe, Junko Fujitake, Yoshifumi Nakaya
We herein report a case of capsular warning syndrome (CWS) that was successfully treated with recombinant tissue plasminogen activator (rt-PA). A 70-year-old woman had repeated stereotyped transient ischemic attacks (TIAs) of right hemiparesis and dysarthria. After hospitalization, argatroban, aspirin, and cilostazol were started but were ineffective. Thirteen hours after the first episode of TIAs, severe symptoms occurred. Magnetic resonance imaging showed acute infarctions in the internal capsule to corona radiata, so we used rt-PA...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28194663/cilostazol-use-is-associated-with-reduced-risk-of-dementia-a-nationwide-cohort-study
#12
Shu-Yu Tai, Chen-Yu Chien, Yu-Han Chang, Yuan-Han Yang
Whether antiplatelet agents have a preventive effect on cognitive function remains unknown. We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population. Patients initiating cilostazol therapy between 1 January 2004 and 31 December 2009 without a prior history of dementia were identified from Taiwan's National Health Insurance database. Participants were stratified by age, sex, comorbidities, and comedication...
February 13, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28194402/corrigendum-unfractionated-and-low-molecular-weight-heparin-and-the-phosphodiesterase-inhibitors-ibmx-and-cilostazol-block-ex-vivo-equid-herpesvirus-type-1-induced-platelet-activation
#13
Tracy Stokol, Priscila B S Serpa, Muhammad N Zahid, Marjory B Brooks
[This corrects the article on p. 99 in vol. 3, PMID: 27909693.].
2017: Frontiers in Veterinary Science
https://www.readbyqxmd.com/read/28183219/cilostazol-may-improve-maturation-rates-and-durability-of-vascular-access-for-hemodialysis
#14
Todd E Russell, Gregory C Kasper, Andrew J Seiwert, Anthony J Comerota, Fedor Lurie
Cilostazol is effective in controlling pathophysiological pathways similar or identical to those involved in nonmaturation and failure of the arteriovenous access. This case-control study examined whether cilostazol would improve maturation rates and durability of vascular access for hemodialysis. The treatment group included 33 patients who received cilostazol for ≥30 days prior to creation of a dialysis access and continued with cilostazol therapy for ≥60 days after surgery. The matched (gender, age, race, diabetes, and the year of surgery) control group included 116 patients who underwent the same procedure but did not receive cilostazol prior to and at least 3 months after surgery...
April 2017: Vascular and Endovascular Surgery
https://www.readbyqxmd.com/read/28178410/strategies-to-extend-thrombolytic-time-window-for-ischemic-stroke-treatment-an-unmet-clinical-need
#15
REVIEW
Ike Dela Peña, Cesar Borlongan, Guofang Shen, Willie Davis
To date, reperfusion with tissue plasminogen activator (tPA) remains the gold standard treatment for ischemic stroke. However, when tPA is given beyond 4.5 hours of stroke onset, deleterious effects of the drug ensue, especially, hemorrhagic transformation (HT), which causes the most significant morbidity and mortality in stroke patients. An important clinical problem at hand is to develop strategies that will enhance the therapeutic time window for tPA therapy and reduce the adverse effects (especially HT) of delayed tPA treatment...
January 2017: Journal of Stroke
https://www.readbyqxmd.com/read/28133890/characterization-of-new-users-of-cilostazol-in-the-uk-spain-sweden-and-germany
#16
Jordi Castellsague, Susana Perez-Gutthann, Brian Calingaert, Christine Bui, Cristina Varas-Lorenzo, Alejandro Arana, Alexandra Prados-Torres, Beatriz Poblador-Plou, Francisca Gonzalez-Rubio, Maria Giner-Soriano, Albert Roso-Llorach, Marie Linder, Anna Citarella, Oliver Scholle, Tilo Blenk, Edeltraut Garbe
PURPOSE: To describe the characteristics of new users of cilostazol in Europe with the aim to support the evaluation of its benefit/risk as used in regular clinical practice before the implementation of labeling changes recommended by the European Medicines Agency. METHODS: New users of cilostazol were identified in populations enrolled in five European health automated databases in the UK (The Health Improvement Network [THIN]), Spain (EpiChron cohort and Information System for the Improvement of Research in Primary Care [SIDIAP]), Sweden (National Registers), and Germany (German Pharmacoepidemiological Research Database [GePaRD]) between 2002 and 2012...
January 30, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28116935/-cilostazol-is-effective-and-safe-option-for-the-treatment-of-intermittent-claudication-results-of-the-noclaud-study
#17
Katalin Farkas, Zoltán Járai, Endre Kolossváry
Intermittent claudication can seriously impair the patients' quality of life. Cilostazol was registered in Hungary in 2014. This study aimed to evaluate the efficacy and safety of cilostazol in patients with intermittent claudication. 1405 patients were enrolled to the 6 months, multicenter, non-interventional trial. From the 1331 patients, who completed the study, the data of 674 patients were subjected to efficacy analysis. Pain free and maximal walking distance and the 6 minute walking test improved significantly at 3 months (78...
January 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28112492/acute-renal-failure-caused-by-cilostazol-in-a-patient-with-alzheimer-s-disease
#18
Hiroshi Nomoto, Yoichiro Matsubara, Yosuke Ichimiya, Heii Arai
No abstract text is available yet for this article.
January 2017: Geriatrics & Gerontology International
https://www.readbyqxmd.com/read/28089463/anti-inflammatory-effects-of-the-selective-phosphodiesterase-3-inhibitor-cilostazol-and-antioxidants-enzymatically-modified-isoquercitrin-and-%C3%AE-lipoic-acid-reduce-dextran-sulphate-sodium-induced-colorectal-mucosal-injury-in-mice
#19
Yumi Kangawa, Toshinori Yoshida, Hajime Abe, Yoshiki Seto, Taishi Miyashita, Michi Nakamura, Tohru Kihara, Shim-Mo Hayashi, Makoto Shibutani
Developing effective treatments and preventing inflammatory bowel disease (IBD) are urgent challenges in improving patients' health. It has been suggested that platelet activation and reactive oxidative species generation are involved in the pathogenesis of IBD. We examined the inhibitory effects of a selective phosphodiesterase-3 inhibitor, cilostazol (CZ), and two antioxidants, enzymatically modified isoquercitrin (EMIQ) and α-lipoic acid (ALA), against dextran sulphate sodium (DSS)-induced colitis. BALB/c mice were treated with 0...
January 12, 2017: Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Für Toxikologische Pathologie
https://www.readbyqxmd.com/read/28073668/drug-eluting-stenting-for-femoropopliteal-lesions-followed-by-cilostazol-treatment-reduces-stent-restenosis-in-patients-with-symptomatic-peripheral-artery-disease
#20
Kan Zen, Mitsuyoshi Takahara, Osamu Iida, Yoshimitsu Soga, Daizo Kawasaki, Shinsuke Nanto, Hiroyoshi Yokoi, Satoaki Matoba
BACKGROUND: Cilostazol improves clinical endovascular therapy outcomes for femoropopliteal (FP) lesions in patients with symptomatic peripheral arterial disease, but whether it also has clinical benefits for patients after drug-eluting stent implantation remains unclear. METHODS: This study is a subanalysis of the ZilvEr PTX for tHe Femoral ArterY and Proximal Popliteal ArteRy (ZEPHYR) study, a prospective multicenter study investigating FP lesions treated with the Zilver (Cook Medical, Bloomington, Ind) paclitaxel-eluting stent...
March 2017: Journal of Vascular Surgery
keyword
keyword
843
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"